Foley Represents Prellis Biologics in Strategic Collaboration with Eli Lilly to Advance Human Antibody Therapeutics

Foley & Lardner LLP served as legal counsel to Prellis Biologics, Inc., a biotechnology company innovating human antibody discovery through organoid and artificial intelligence enabled technology, in its multi-target drug discovery and development collaboration with Eli Lilly and Company (Lilly).

The strategic partnership combines Prellis’ first-of-a-kind biological AI with Lilly’s renowned research to accelerate the development of high-quality, next-generation human antibody therapeutics for multiple disease targets. The joint effort will leverage Prellis’ proprietary lymph node organoid technology system that rapidly recapitulates human immune response in vitro combined with rapid AI-based optimization for enhanced therapeutic efficacy, safety, and manufacturability. 

Prellis, the first company to design drugs by combining a living biological system with generative AI refinements, will receive an up-front payment, development and sales milestones, and royalties for the licensed antibodies.

The Foley team was led by life sciences transactional and intellectual property partner Tom Anderton and included tax partner Raj Tanden and intellectual property associate Sarah Waste.